rs193922297
Variant summary
Our verdict is Pathogenic. The variant received 13 ACMG points: 13P and 0B. PM5PP2PP3PM2_SupportingPS4PP1_Strong
This summary comes from the ClinGen Evidence Repository: The c.449T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to serine at codon 150 (p.(Phe150Ser)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.983, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has a gnomAD v4.0.0 Popmax filtering allele frequency of 0 (below the MDEP threshold of 0.000003), and ≤ 2 copies observed in the European non-Finnish population and any other subpopulation, thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting). This variant was identified in at least 28 unrelated individuals with hyperglycemia (PS4; PMIDs: 15305805, 30191644, internal lab contributors). This variant segregated with hyperglycemia, with at least 19 informative meioses in multiple families (PP1_Strong; internal lab contributors). Another missense variant, c.449T>A p.Phe150Tyr has been interpreted as pathogenic by the ClinGen MDEP, and p.Phe150Ser has a greater Grantham distance (PM5). In summary, c.449T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0 approved 8/11/2023): PS4, PP1_Strong, PM2_Supporting, PP3, PP2, PM5. LINK:https://erepo.genome.network/evrepo/ui/classification/CA213784/MONDO:0015967/086
Frequency
Consequence
NM_000162.5 missense
Scores
Clinical Significance
Conservation
Publications
- hyperinsulinism due to glucokinase deficiencyInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet
- maturity-onset diabetes of the young type 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- monogenic diabetesInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- diabetes mellitus, noninsulin-dependentInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- permanent neonatal diabetes mellitus 1Inheritance: AR Classification: STRONG, MODERATE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
- transient neonatal diabetes mellitusInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
- maturity-onset diabetes of the youngInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- permanent neonatal diabetes mellitusInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 13 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GCK | NM_000162.5 | c.449T>C | p.Phe150Ser | missense_variant | Exon 4 of 10 | ENST00000403799.8 | NP_000153.1 | |
| GCK | NM_033507.3 | c.452T>C | p.Phe151Ser | missense_variant | Exon 4 of 10 | NP_277042.1 | ||
| GCK | NM_033508.3 | c.446T>C | p.Phe149Ser | missense_variant | Exon 5 of 11 | NP_277043.1 | ||
| GCK | NM_001354800.1 | c.449T>C | p.Phe150Ser | missense_variant | Exon 4 of 11 | NP_001341729.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461808Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727216 show subpopulations
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Maturity-onset diabetes of the young type 2 Pathogenic:2
The GCK c.449T>C variant is classified as Likely Pathogenic (PS4_Moderate, PM2_Supporting, PS3_Supporting, PP3, PP4_Moderate). The GCK c.449T>C variant is a single nucleotide change in exon 4/10 of the GCK gene, which is predicted to change the amino acid phenylalanine at position 150 in the protein to serine. The variant has been reported multiple times in the literature in unrelated affected individuals with a clinical presentation of MODY (PMID: 30191644, 14517946, 9662401, 34789499) (PS4_Moderate). This variant is absent from population databases (PM2_Supporting). A yeast hybrid complementation functional study completed by Gersing et al, 2013 demonstrated a reduction in human GCK activity with this variant compared to non-pathogenic GCK variants/ WT control (PMID: 37101203, PS3_Supporting). Computational predictions support a deleterious effect on the gene or gene product (PP3). The clinical features of this case are highly specific for the GCK gene, the family history is consistent with the mode of inheritance of this condition and this patient has a well-defined syndrome with little overlap with other clinical presentations (PP4_Moderate). The variant has been reported in dbSNP (rs193922297) and in the HGMD database as disease causing (CM980893). It has been reported as Pathogenic/Likely pathogenic by other diagnostic laboratories (ClinVar Variation ID: 36218). -
- -
Monogenic diabetes Pathogenic:1
The c.449T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to serine at codon 150 (p.(Phe150Ser)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.983, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has a gnomAD v4.0.0 Popmax filtering allele frequency of 0 (below the MDEP threshold of 0.000003), and <=2 copies observed in the European non-Finnish population and any other subpopulation, thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting). This variant was identified in at least 28 unrelated individuals with hyperglycemia (PS4; PMIDs: 15305805, 30191644, internal lab contributors). This variant segregated with hyperglycemia, with at least 19 informative meioses in multiple families (PP1_Strong; internal lab contributors). Another missense variant, c.449T>A p.Phe150Tyr has been interpreted as pathogenic by the ClinGen MDEP, and p.Phe150Ser has a greater Grantham distance (PM5). In summary, c.449T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0 approved 8/11/2023): PS4, PP1_Strong, PM2_Supporting, PP3, PP2, PM5. -
not provided Pathogenic:1
Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 30191644, 9662401, 14517946, 14517956, 18271687, 32533152, 32041611, 15305805) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at